KR940008688A - Zinc Tablets Chelated by Essential Fatty Acids - Google Patents
Zinc Tablets Chelated by Essential Fatty Acids Download PDFInfo
- Publication number
- KR940008688A KR940008688A KR1019930021293A KR930021293A KR940008688A KR 940008688 A KR940008688 A KR 940008688A KR 1019930021293 A KR1019930021293 A KR 1019930021293A KR 930021293 A KR930021293 A KR 930021293A KR 940008688 A KR940008688 A KR 940008688A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- fatty acid
- fatty acids
- essential fatty
- zinc
- Prior art date
Links
- 235000004626 essential fatty acids Nutrition 0.000 title claims abstract 14
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract 7
- 239000011701 zinc Substances 0.000 title claims abstract 7
- 229910052725 zinc Inorganic materials 0.000 title claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 18
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims abstract 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract 7
- 229930195729 fatty acid Natural products 0.000 claims abstract 7
- 239000000194 fatty acid Substances 0.000 claims abstract 7
- 150000004665 fatty acids Chemical class 0.000 claims abstract 7
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract 7
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract 7
- 239000000203 mixture Substances 0.000 claims abstract 6
- 239000003531 protein hydrolysate Substances 0.000 claims abstract 6
- 235000005074 zinc chloride Nutrition 0.000 claims abstract 6
- 239000011592 zinc chloride Substances 0.000 claims abstract 6
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 3
- 239000002243 precursor Substances 0.000 claims abstract 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract 2
- 239000002775 capsule Substances 0.000 claims abstract 2
- 235000020778 linoleic acid Nutrition 0.000 claims abstract 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 108010009736 Protein Hydrolysates Proteins 0.000 abstract 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 2
- 229940114079 arachidonic acid Drugs 0.000 abstract 1
- 235000021342 arachidonic acid Nutrition 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
불포화 지방산에 의해 킬레이트화된 결정체 아연을 포함하는 조성물은 식이 및 치료의 목적을 위하여 지방산 및 아연 모두의 편리한 출처를 제공한다.Compositions comprising crystalline zinc chelated by unsaturated fatty acids provide a convenient source of both fatty acids and zinc for dietary and therapeutic purposes.
바람직하게는 불포화 지방산은 필수지방산을 함유한다.Preferably the unsaturated fatty acid contains essential fatty acids.
필수지방산은 플로스타글란딘 및 플로스타글란딘 선구물질로 구성된 그룹으로 부터 선택된 지방산을 포함할 수 있다.Essential fatty acids may include fatty acids selected from the group consisting of flostaglandin and flostaglandin precursors.
대표적으로 필수지방산은 적어도 리놀산, 리놀린산 및 아라키돈산으로 구성된 그룹으로 부터 선택된 적어도 한개의 지방산을 포함한다.Typically essential fatty acids include at least one fatty acid selected from the group consisting of at least linoleic acid, linoleic acid and arachidonic acid.
제약학적 조성물은 (1)불포화 지방산, (2)염화아연, (3)단백질 가수분해물, (4)적어도 한개의 제약학적으로 허용되는 부형제를 포함할 수 있다.The pharmaceutical composition may comprise (1) unsaturated fatty acids, (2) zinc chloride, (3) protein hydrolysates, and (4) at least one pharmaceutically acceptable excipient.
제약학적 조성물은 정제 또는 캡슐 형태로 제조될 수 있고, 바람직하게는 제약학적 조성물에서 필수지방산, 염화아연 및 단백질 가수분해물이 10:1:5의 비율로 존재한다.The pharmaceutical composition may be prepared in the form of tablets or capsules, and in the pharmaceutical composition, essential fatty acids, zinc chloride and protein hydrolysates are present in a ratio of 10: 1: 5.
바람직하게는 제약학적 조성물은 정제당 약 20밀리그램의 아연을 함유한다.Preferably the pharmaceutical composition contains about 20 milligrams of zinc per tablet.
제약학적 조성물은 당뇨병의 치료에 유용하다.Pharmaceutical compositions are useful for the treatment of diabetes.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.
Claims (16)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96487992A | 1992-10-22 | 1992-10-22 | |
| US07/964,879 | 1992-10-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR940008688A true KR940008688A (en) | 1994-05-16 |
| KR100312245B1 KR100312245B1 (en) | 2002-02-19 |
Family
ID=66825053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019930021293A KR100312245B1 (en) | 1992-10-22 | 1993-10-14 | Zinc Tablets Chelated by Essential Fatty Acids |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100312245B1 (en) |
-
1993
- 1993-10-14 KR KR1019930021293A patent/KR100312245B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100312245B1 (en) | 2002-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2122409C1 (en) | Treatment with fatty acids | |
| ATE204178T1 (en) | METHOD FOR TREATING AND PREVENTING TYPE 1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN | |
| KR920000324A (en) | Essential Fatty Acid Treatment | |
| ATE67677T1 (en) | MEDICATIONS FOR ORAL ADMINISTRATION CONTAINING 10 TO 240 MG OF DIHYDROPYRIDINE IN A SINGLE DOSE. | |
| DE69331409D1 (en) | ORAL 1ALPHA HYDROXYPREVITAMIN D | |
| UA41446C2 (en) | Use of fumagilol or its derivatives for preparing drugs intended for treating intestinal infection and pharmaceutical composition | |
| IS1858B (en) | Method of producing a pharmaceutical composition in the form of pellets for the treatment of intestinal inflammation | |
| KR940018089A (en) | Prevention and treatment for radiation damage of internal tissue | |
| KR840003414A (en) | Pharmaceutical compositions containing 3-hydroxybutanoic acid or salts derived from these acids, and compounds derived from 3-hydroxybutanoic acid that can be used as pharmaceuticals | |
| EP0674511A1 (en) | ANTIPYRETIC AND ANALGETIC METHODS AND COMPOSITIONS CONTAINING OPTICALLY PURE R-KETOROLAC. | |
| PT83474B (en) | A process for the preparation of a pharmaceutical composition comprising 2- (2-fluoro-4-biphenyl) propionic acid or a pharmaceutically acceptable salt thereof | |
| ATE99172T1 (en) | USE OF ACETYL-L-CARNITINE IN TREATMENT OF CATARACT, AND PHARMACEUTICAL COMPOSITIONS FOR SUCH TREATMENT. | |
| KR920700630A (en) | Expression-promoted / enhanced antipyretic reactions | |
| IL97796A0 (en) | Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation | |
| KR910005858A (en) | Fatty acid therapy | |
| BR8800763A (en) | PROCESS FOR THE PREPARATION OF A DELAYED EFFECT PRODUCT CONTAINING DILTIAZEM, FOR ONE DAY ADMINISTRATION | |
| ATE69164T1 (en) | MEDICATIONS FOR THE TREATMENT OF URAEMIA. | |
| KR910009715A (en) | Nonionic X-Ray Contrast with High Iodine Content | |
| KR920702225A (en) | Pharmaceutical composition | |
| KR940003552A (en) | Prevention and treatment of calcification using fatty acids | |
| KR940013503A (en) | Pharmaceutical compositions for the prevention or treatment of atherosclerosis | |
| KR940008688A (en) | Zinc Tablets Chelated by Essential Fatty Acids | |
| JPS6216415A (en) | Medicinal composition for treating syndrome before menses and therapy therefor | |
| KR900700102A (en) | Long-lasting composition of propaphenone and quinidine for the treatment of heart disease | |
| ATE86965T1 (en) | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF ADRENOLEUCODYSTROPHY. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19931014 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19980807 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19931014 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20000525 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20010117 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20010725 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20011008 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20011009 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20050709 |